insights_auto
Why is GRAL up 2.97%?
Dive Deeperchevron_right
GRAL:NASDAQ
Grail Inc
$136.57
arrow_upward
+2.97%(+3.94) 1D
$136.57
0.00% (0.00)
bedtimeAfter hours
Closed: Sep 29, 4:00:01 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GRAL...
Open
$132.75
High
$140.88
Low
$131.20
Mkt. cap
6.10B
Avg. vol.
1.11M
Volume
314.00
52-wk high
$140.88
52-wk low
$41.50
EPS
-$9.75
Shares outstanding
44.67M
No. of employees
910
Open
$132.75
High
$140.88
Low
$131.20
Mkt. cap
6.10B
Avg. vol.
1.11M
Volume
314.00
52-wk high
$140.88
52-wk low
$41.50
EPS
-$9.75
Shares outstanding
44.67M
No. of employees
910
News stories
From web sources and news partners
Stock Traders Daily
·
1 day ago
(GRAL) Risk Channels and Responsive Allocation
StocksToTrade
·
1 day ago
GRAL Stock Rockets Higher As Traders Hunt Momentum
TipRanks
·
1 day ago
Analysts’ Bullish Call Sends GRAIL Stock Surging
Pluang
·
1 day ago
Grail's stock jumps 55% after positive FDA advi...
Profile
GRAIL, Inc. is an American biotechnology company based in Menlo Park, California founded in 2015 seeking to develop an early cancer screening test for people who do not have symptoms. As a startup it was a subsidiary of Illumina, which bought it outright in 2021.
In June 2021, GRAIL launched their liquid biopsy, or multi-cancer early detection test, which they called Galleri test. In 2023, EU regulators ordered Grail to be spun-out from Illumina which was completed on June 24, 2024. Wikipedia
About Grail Inc
CEO-
Employees910
Founded2015
HeadquartersMenlo Park, California, United States
SectorBiotechnology
Websitegrail.com